Spyre Therapeutics, Inc. has filed a Form 8-K with the Securities and Exchange Commission (SEC) regarding a significant stock offering. The company plans to raise approximately $350 million through the sale of its common stock at a public offering price of $85 per share. This filing is important for investors and stakeholders as it outlines the company’s financial strategies and future plans.
Spyre Therapeutics is a biopharmaceutical company focused on developing innovative therapies for various medical conditions. The Form 8-K is a current report that companies must file with the SEC to announce major events that shareholders should know about. This particular filing, accession number 0001628280-26-065291, details the company's entry into a material definitive agreement.
Details of the Filing
According to the filing, dated October 5, 2026, Spyre entered into an underwriting agreement with Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated. The agreement pertains to the offering of 4,117,648 shares of common stock. Additionally, the underwriters have a 30-day option to purchase up to an additional 617,647 shares on the same terms.
"The gross proceeds to the Company from the Offering are expected to be approximately $350.0 million, before deducting underwriting discounts and commissions and estimated offering expenses," the filing states.
The company plans to use the net proceeds from the offering to advance its programs in Gastroenterology, Rheumatology, and Dermatology. This includes funding preclinical studies, clinical trials, and preparations for Phase 3 development of its therapies. Notably, Spyre intends to advance a new program for SPY072, targeting hidradenitis suppurativa.
Moreover, Spyre may also allocate some of the proceeds to enhance its general infrastructure and potentially invest in or acquire new businesses, technologies, or products.
Potential Impact
This offering could significantly impact various stakeholders, including investors, healthcare professionals, and patients. For investors, the successful completion of this offering may enhance the company’s financial position and support its growth initiatives. Healthcare professionals may benefit from the advancements in treatments that the funding will support, particularly in areas where current therapies are limited. Patients suffering from conditions targeted by Spyre's therapies could see improved treatment options as a result of the funding.
What's Next?
The filing does not specify what happens next, but it indicates that the offering is expected to close on or about October 7, 2026, pending the satisfaction of customary closing conditions. Investors and interested parties will likely be watching closely for updates regarding the completion of the offering and how Spyre will utilize the funds raised.